Informatics

US Laboratory Information Management System Market Report 2023-2028: Cloud-Based LIMS Soars, Remote Access Demand Propels Market to $1.06 Billion

Retrieved on: 
Wednesday, February 14, 2024

DUBLIN, Feb. 13, 2024 /PRNewswire/ -- The "US Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 13, 2024 /PRNewswire/ -- The "US Laboratory Information Management System (LIMS) Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The US Laboratory Information Management System (LIMS) market has been meticulously analyzed in the latest research publication added to our extensive database of industry reports.
  • The study, which focuses on market data from 2023 to 2028, reveals the continuous growth and technological advancements in the field of laboratory informatics.
  • The in-depth report encompasses current market scenarios, size, and forecasts, while providing detailed segmentation and trends that are influencing market dynamics.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

EQS-News: Benedikt Bonnmann succeeds Torsten Wegener on adesso SE Executive Board / Continued strategic focus on forward-thinking artificial intelligence technologies

Retrieved on: 
Monday, February 12, 2024

The adesso SE Supervisory Board has appointed Benedikt Bonnmann to the Executive Board of adesso SE with effect from 1 April 2024.

Key Points: 
  • The adesso SE Supervisory Board has appointed Benedikt Bonnmann to the Executive Board of adesso SE with effect from 1 April 2024.
  • Most recently, he headed up the Digital Horizontals business area as Executive Director and was personally responsible for the Data & Analytics division.
  • By making this appointment, the Supervisory Board continues to set up the adesso Group to take further advantage of the considerable business opportunities offered by artificial intelligence.
  • He will also continue to hold key Advisory Board positions for adesso, including on the committees of material.one, Bluplanet und adesso Turkey.

Contributing to Efficient Development of Metal Thin Film Materials by Using Chemicals Informatics and Materials Informatics

Retrieved on: 
Friday, February 9, 2024

CI is a Hitachi High-Tech's proprietary service that uses AI to analyze public data such as patents and select optimal materials for development.

Key Points: 
  • CI is a Hitachi High-Tech's proprietary service that uses AI to analyze public data such as patents and select optimal materials for development.
  • The PoC clarified that even new materials with no accumulated past experimental data can be developed more efficiently by combining Hitachi High-Tech's MI with CI.
  • This eliminates the document research and round-robin test with experimental designs(1), thereby improving the efficiency of developing new materials.
  • In the past, determining optimal conditions for materials used in development, including ideal combination ratios, volumes and temperatures, involved numerous repeated experiments.

Anju Software Unveils Strategies for Data-Driven Decision-Making in Clinical Research at SCOPE Orlando 2024

Retrieved on: 
Thursday, February 8, 2024

FORT LAUDERDALE, Fla., Feb. 8, 2024 /PRNewswire/ -- Anju Software , a prominent provider of software solutions for the life sciences industry, is thrilled to announce its participation in the 15th annual SCOPE Summit for Clinical Ops Executives from February 11-14, 2024, in Orlando, Florida.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 8, 2024 /PRNewswire/ -- Anju Software , a prominent provider of software solutions for the life sciences industry, is thrilled to announce its participation in the 15th annual SCOPE Summit for Clinical Ops Executives from February 11-14, 2024, in Orlando, Florida.
  • SCOPE Orlando 2024, a premier clinical operations conference, offers a 200-event exhibit hall, cross-department panels, and three plenary keynotes, providing attendees with networking opportunities and insights into the latest trends in clinical trials.
  • The focus of this presentation is on establishing a robust capability for data-driven decision-making in clinical research.
  • Additional highlights of SCOPE Orlando 2024 include keynotes such as Pfizer's Robert Goodwin discussing "Time is Life: Pfizer's Approach to Accelerating Clinical Development" on Monday, February 12.

Nabla Appoints Clinical Leader Dr. Ed Lee as its Chief Medical Officer

Retrieved on: 
Thursday, February 8, 2024

Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development

Key Points: 
  • Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development
    BOSTON, Feb. 8, 2024 /PRNewswire/ -- Nabla , the leading ambient AI assistant for practitioners, today announced the appointment of Ed Lee, MD, MPH , as Chief Medical Officer.
  • He brings his expansive clinical expertise, executive experience, and Nabla Copilot implementation insights to the company to help refine and enhance the product and deployment strategy.
  • As Chief Medical Officer, Dr. Lee will be instrumental in shaping Copilot's clinical strategy and product roadmap, including RCM optimization, and he will provide feature refinement and enhancement recommendations to solidify Nabla as a leader in healthcare ambient AI.
  • He will also represent Nabla at the American Medical Informatics Association (AMIA), offering insights on the field of clinical informatics and contributing to AMIA policy responses.

Fujifilm’s Synapse® Vendor Neutral Archive (VNA) Earns “Best in KLAS” for Fifth Consecutive Year

Retrieved on: 
Wednesday, February 7, 2024

Best in KLAS is an industry insights initiative by KLAS Research that recognizes software and services companies that excel in helping healthcare professionals improve patient care.

Key Points: 
  • Best in KLAS is an industry insights initiative by KLAS Research that recognizes software and services companies that excel in helping healthcare professionals improve patient care.
  • “Earning Best in KLAS for VNA for the fifth consecutive year is truly an honor as it underscores our customer’s unwavering trust in our technology and business,” says Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation.
  • The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation,” says Adam Gale, Research CEO, KLAS.
  • This includes DICOM and non-DICOM objects to ensure the full patient imaging picture is available to those who need it.

Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over Competitors

Retrieved on: 
Wednesday, February 7, 2024

ALEXANDRIA, Va., Feb. 7, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, announced today new data that showcases the performance of ControlCheck™, the company's next generation of drug diversion monitoring. A new data analysis comparing ControlCheck against other industry solutions from Q1 to Q4 2023 found ControlCheck 6.6 times more likely to detect diversion, setting a new standard for medication safety and security.

Key Points: 
  • ALEXANDRIA, Va., Feb. 7, 2024 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, announced today new data that showcases the performance of ControlCheck™, the company's next generation of drug diversion monitoring.
  • During this same period, ControlCheck identified a staggering 808 confirmed cases of drug diversion showcasing its unparalleled efficacy in safeguarding healthcare institutions.
  • Additionally, ControlCheck revealed 9 out of 10 of those diversion events were attributed to Registered Nurse personnel.
  • "At Bluesight, our mission has always been to advance patient safety through cutting-edge technology," said Kevin MacDonald, Co-founder & CEO of Bluesight.

Sonitor Technologies, Inc. Ranked #1 in 2024 Best in KLAS Real-Time Locating Systems

Retrieved on: 
Wednesday, February 7, 2024

Sonitor Technologies, Inc. is excited to announce that they are ranked Best in KLAS vendor of Real-Time Locating Systems (RTLS) in the 2024 Best in KLAS: Software & Services report .

Key Points: 
  • Sonitor Technologies, Inc. is excited to announce that they are ranked Best in KLAS vendor of Real-Time Locating Systems (RTLS) in the 2024 Best in KLAS: Software & Services report .
  • “We are proud to be recognized as the top performing RTLS company in the 2024 Best in KLAS report,” says Matt Crane, CEO for Sonitor Technologies, Inc. “This recognition proves our customer-first focus combined with leading technology innovation is highly valued by our customers.
  • “The recognition by KLAS Research highlights our ability to generate real-time actionable locating data so that healthcare systems can succeed in that mission.”
    The Best in KLAS report by KLAS Research collects direct feedback and evaluations from active RTLS users and customers in the healthcare industry.
  • Winning a Best in KLAS award, therefore, is not just about recognition; it shows the trust and confidence that healthcare providers place in the winning vendors,” shares Adam Gale, KLAS Research CEO.

Bayer AG Enters Into Agreement With TetraScience to Ignite Innovation by Maximizing the Value of Its Scientific Data

Retrieved on: 
Monday, February 5, 2024

Bayer AG (BAYRY), a leading global pharmaceutical and biotechnology company, and TetraScience , the Scientific Data and AI Cloud company, today announced an agreement aimed at maximizing the value of scientific data and driving innovation.

Key Points: 
  • Bayer AG (BAYRY), a leading global pharmaceutical and biotechnology company, and TetraScience , the Scientific Data and AI Cloud company, today announced an agreement aimed at maximizing the value of scientific data and driving innovation.
  • "By maximizing the value of our scientific data and leveraging advanced data management and data science solutions, we can unlock new insights and opportunities for breakthrough innovations.
  • “Together, we will continue to push the boundaries of discovery by maximizing the value of scientific data and opening the path to AI.
  • Supporting Bayer’s relentless focus on unrestricted scientific innovation with the Tetra Scientific Data and AI Cloud will help solve some of the greatest human challenges.”